Life Sciences Archive » November, 2017

Life Sciences - November, 2017

320 articles

• FDA Chief Reveals New Openness To Quicker Drug Approvals
• Galena Class Settlement Must Proceed, Del. Court Says
• Idaho Doc Gets 16 Years For Illegal Opioid Prescriptions
• JPML Open To Opioid MDL Despite Concerns About Size
• Roche Drops Medical Supply Co. From $89M Test Strips Suit
• Mass. DA Wants 134 Tainted Drug Convictions Thrown Out
• NJ Panel Advances Bill To Close Loophole For Opioid Access
• Sexual Enhancement Supplements Recalled For Health Risk
• J&J Can't Escape $110M Verdict In Mo. Talc Cancer Trial
• Ariad, Investors Strike $3.5M Deal Over Cancer Drug Outlook
• The Billing Evolution: How Far Along Is Your Firm?
• 10 Tips For Effective Practice Before The 5th Circ.
• J&J Unit Workers Say Biz Knew Pelvic Mesh Device Risks
• Reckitt, Generics Makers Settle Mucinex Antitrust Case
• Atty Seeks Arbitration For Ex-Pot Co. Exec's Malpractice Suit
• Judge Tosses 24 New Complaints In Eliquis MDL
• BioChemics Obtains 11th-Hour Deposit On $17M Owed To SEC
• Pharma Marketers Can't Escape Tricare Kickback Suit
• PetSmart Beats Fraud Claims Over Prescription Cat Food
• Teamsters Files Suit Against Drug Cos. For Opioid Push
• HHS Pick Bashes ACA, Sweats Drug Prices On Capitol Hill
• Calif. Appeals Court Upholds BOE's $17M Sales Tax Reshuffle
• Pharmacies Abused Federal Workers' Comp, FCA Suit Says
• Mich. Law Bars Some Risperdal Suits, Pa. Court Finds
• Preparing Your Company Witnesses For The Gotcha Question
• The Latest Trends In Drug Monopolies
• With Wave Of Suits, Chicago Turns Focus To Residents' Rights
• Judging A Book: Saris Reviews 'Locking Up Our Own'
• J&J Moves To Duck Pfizer Suit Over Remicade Biosimilar
• J&J Unit Didn't Provide Pelvic Mesh Warning, Witness Says
• Stryker Unit Settles Biomet Trade Secret Suit
• Altor Investor Seeks Appraisal After $290M NantCell Deal
• Feds Point To Email Trove In Ex-Katten Atty Fraud Trial
• Feds Say Ex-NYU Scientist Entertained Dancer On Gov't Dime
• Pharma CEO Charged With Stealing $1.5M From Investors
• FDA Warning Wire: Issues At Pharmacy Linked To Vision Loss
• TTAB Greenlights Boehringer's 'Breathless' Trademark
• Akorn, Investors Get Initial OK For $24M Accounting Deal
• Warren Asks Trump's HHS Pick About ACA, Drug Prices
• PE-Backed Medpace Unveils 4M-Share Secondary Offering
• Deals Rumor Mill: Siemens Healthineers, Uber, Albea
• OIG Revokes Patient Charity's Kickback Liability Protection
• Allergan Hit With Antitrust Suit Over Deal With Tribe
• Fed. Circ. Guidance For Pharma Method-Of-Use Patent Cases
• The Broad Reach Of Medicare Act's Preemption Provision
• Arrested Insys Founder Kicks Off Jog-Blocking Ankle Monitor
• 'Seminal' Allergan Cases Test Copycat Drug Limits
• J&J Unit Put Pelvic Mesh Profit Over Safety, NJ Jury Told
• Shire Trade Secrets Complaint Against Ultragenyx Accelerated
• 7th Circ. Can't Find Bad Faith In Purchase Of Bacteria Co.
• Maquet Sues Abiomed Over Blood Pump Patent
• Del. Justices Reject Third Chance For BioScrip Investors
• Shkreli Mentor And Investor Says He Lied To Feds
• 3 Life Sciences Cos., 1 Bank Launch IPOs Totaling $481M
• Pfizer Wants Justices To Review Lipitor Antitrust Ruling
• Pfizer Reaches $94M Settlement Over Celebrex Claims
• 'Reckless' Adviser Doomed Copy Of Biogen Blockbuster: Suit
• Treasury, IRS Appeal Invalidation Of Anti-Inversion Rule
• DOJ Closes J&J Witness Tampering Investigation
• CR Bard Loses Bid To Escape Heart Filter MDL
• Justices Decline To Review Removal Of Vascular Filter Suits
• Shkreli Deal Legit, Investor Says Ex-Katten Atty Told Him
• No New Trial For Parents Suing Abbott Over Birth Defects
• Fed. Circ. OKs Ax Of Lilly's Axiron Patent, Allows Generics
• Ex-Virginia Tech Professor Charged In Alleged Grant Fraud
• Florida Sued For Dragging Feet On Medical Pot Licenses
• Medicis, Solodyn Buyers Duel For Quick Wins In Antitrust MDL
• Amerisource Cuts $625M FCA Deal Over Repacked Drugs
• What Attorneys Get Wrong About Native American Law
• Amicus Arguments For And Against Inter Partes Review
• Amarin Case Demonstrates Limits Of ITC Jurisdiction
• Does Your D&O Policy Really Cover Gov't Investigations?
• How Associate Bonuses May Highlight BigLaw's Profit Gap
• Akorn Reaches $24M Deal To End Investors' Accounting Suit
• Dialysis Patients Face Undoing By Experts In Fresenius MDL
• Sanofi Wins Fees After Ditching 'Clearly Frivolous' FCA Suit
• Ex-Galleon Trader Says He Didn't Report Shkreli To Feds
• DOJ Cleared To Split Up $350M Shire Deal For Whistleblowers
• FDA Warning Wire: Insomnia Drug Promo Omits Risk Info
• Pharma Groups Pressure FDA On Drug Innovation, Access
• Fla. Hospitals Launch Wide-Ranging Opioid Liability Suit
• 'Willfulness' In Civil FBAR Cases Comes Down To The Facts
• Pepper Hamilton Regains Life Sciences Duo In Philly
• Opioid Insurance Litigation Is Mounting With Mixed Results
• Ex-Galleon Trader Details Shkreli Vendetta At Ex-Katten Atty Trial
• Globus Says Ex-Engineer Took Trade Secrets To Stryker
• DOD Slow To Target Rising Rx Costs, Fraud Risks: Watchdog
• Abbvie Says Medical Mutual Being 'Cagey' In Androgel MDL
• Fed. Circ. Urged To Not Review Defense In $200M Patent Suit
• J&J Says Applicant Must Arbitrate Background Check Claims
• EU Drug Agency Packs Bags For Amsterdam Amid Brexit
• SEC Judge Refuses To Bar Shkreli Without Tie To Adviser
• Deal Expected In Insurer's Actos Cancer Suit Against Takeda
• Don't Waste This Planning Cycle: Year-End Strategies
• Mass Tort Firm Nears Settlement In $110M Contractor Suit
• Restasis Buyers Hit Allergan With Antitrust Suit
• Tribe Invokes Immunity In $10M Cannabis Contract Dispute
• CytRx Investors Seek Cert. In Suit Over Cancer Drug Trial
• Criticism Of FDA Citizen Petitions Is Often Misguided
• Hatch-Waxman And Copying: An Exception To The Exception?
• Orexigen Seeks Toss Of Suit Over Drug Trial Leaks
• Texas Justices Shelve J&J Mesh Case After Appeal Dropped
• Catheter IP Row Settles After Fed. Circ. Kills $20M Ruling
• VC-Backed Stitch Fix Ekes Gain After $120M IPO Prices Low
• Colgate Says Experts' Nix Undermines Philly Talc Case
• From Snaps To Tweets: The Craft Of Social Media Discovery
• Health Hires: Hogan Lovells, Jones Day, Morgan Lewis
• USPTO Defends Win-Or-Lose Fee Rule To Full Fed. Circ.
• Scientists See No Solution As Talc Cases Test The System
• Taxation With Representation: Andrews, Mayer, Jones, Delaby
• A Post-Lexmark Plan For Multiple Inventive Methods Of Use
• Consultant Contracts Can Create California Connection
• Tribe Seeks Injunction Against Hemp-Seizing Calif. County
• Tech Co. Must Face Suit Over Patient Monitoring System
• Gov't Asks 2nd Circ. To Toss Pfizer's $8.3M Interest Case
• NantKwest Investor Sues Insiders Over Restatements
• Shkreli Auditor Says Investor Settlements Seemed Legit
• Senate Sends $700B Defense Bill To Trump's Desk
• Insys Founder Denies Plot To Bribe Doctors Over Opioid Spray
• PTAB Chief Debunks Patent Myth As Petitions Soar
• 3rd Circ. Won't Revive FCA Suit Against CVS Caremark
• Xarelto Witness-Tampering Testimony Barred, For Now
• Pharma Trading Suspects Denied Bid To Trim Suit
• Chinese Fintech Jianpu Raises $180M After IPO Prices Low
• Chicago's Suit Over Opioids Paused Ahead Of MDL Ruling
• Consumers Get State Classes Certified In Bayer Vitamin Row
• Illinois Biometrics Privacy Suits Bring Insurance Questions
• Tobacco Groups Blast FDA For 'Massive' Speech Restriction
• FTC's Ohlhausen Sees Light At End Of Pay-For-Delay Tunnel
• House Passes Tax Bill With Deep Cuts For Businesses
• Auxilium Not Liable For Man's Heart Attack, Ill. Jury Finds
• An Interview With Former DHS Secretary Jeh Johnson
• J&J, Talc Supplier Not Liable For Woman's Asbestos Illness
• Senate Bill Targets Opioid Safety For Vets Not Treated At VA
• J&J Slammed With $247M Verdict In Texas Hip Bellwether
• Hurdles To Consider When Securing A Personnel File
• Calif.'s New Focus On Drug Pricing Transparency
• VisionAid Can't Get Own Atty In Firing Suit, 1st Circ. Says
• Auxilium's First Testosterone Bellwether Heads To Jury
• Eye-Drug Compounder Can't Dodge Allergan Suit
• Abbott Won't Face Autism Claim In Depakote Birth Defect Trial
• J&J, Bayer Fight Ex-FDA Head's Xarelto Warning Testimony
• Aveo Investors Get Certification In Cancer Drug Suit
• BioScrip Investors Ask Del. Justices For 3rd Try At Suit
• Endo Concealed Unit's Alleged Price-Fixing, Investors Say
• Bass Gets Fed. Circ. Win On Drug Patent From Sidelines
• Gov't Says High Court Should Take Up Vitamin C Price-Fix Suit
• Online Health Network Hit With $179M Judgment In FTC Probe
• Ex-Katten Atty Wanted Shkreli Loan Disclosed, Jury Hears
• 5th Circ. Won't Restore $7.5M Jury Award In Contract Suit
• Shanghai Pharma To Pay $557M For Cardinal Health China Biz
• Split PTAB Denies Pfizer's Challenge To Rituxan Patent
• GE Seeks Damages Trial After $43.8M Machine-Parts Verdict
• DC Circ. Threads Needle On Docs Privilege In FTC Row
• State AGs Want Separate Track In Generic Price-Fixing MDL
• Bipartisan Bill Would Block 340B Drug Program Cuts
• PharMerica Kickbacks Not Public Knowledge, 3rd Circ. Told
• China's FDA Reform Will Encourage Life Science Innovation
• Judging A Book: Gilstrap Reviews 'Alexander Hamilton'
• Deliberate Discovery Responses Shift Onus Onto Opponent
• Opioid Epidemic Brings Ramifications For Physicians
• Depakote Judge Denies Abbott Bid To Restrict Exec Subpoena
• Janssen, Samsung Subsidiary Drop Suit Over Remicade Copy
• 9th Circ. Urged to Let Arbitrators Get Docs From Third Parties
• Fed. Circ. Affirms Toss Of Hyptertension Treatment IP
• US House Passes Compromise $700B Defense Bill
• DOJ Fights Whistleblower 'Windfall' In $280M FCA Deal
• Feds Extend Immunity To Ex-Retrophin Exec Over Hacking Claim
• Cherokee Opioid Fight Should Inspire Other Tribes, AG Says
• Ex-FDA Commissioner Slams Xarelto Warnings In Philly Trial
• RI Atty Fights Texas Jurisdiction In Mesh Row Before Justices
• J&J Hip Implant Patients Seek Big Damages From Texas Jury
• Injectable Silicone Linked To Disfigurement, Deaths, FDA Says
• The Case For Creating A Mediation Department At Your Firm
• FDA Warns Of Deaths Linked To Opioid-Like Kratom
• Walgreens Hit With Suit Over Sale Of J&J Talc Products
• Miramar Directors Ready To Put Sientra Deal Suit To Bed
• Peruvian Food Co. Camposol Files $345M Dual-Listed IPO
• Woman Seeks $24M As Trial Over Asbestos, J&J Talc Closes
• Ex-Katten Atty Trial Rocked By Claims Of Witness' Cybercrime
• Hospitals Sue HHS Over Big Cut To 340B Drug Payments
• 3 Cos. Price IPOs Raising $410M Led By Chinese Lender
• J&J Hip Implant Jury Won't Hear Witness Tampering Claim
• Biotech Co. Wants Investors' Stock-Drop Suit Tossed
• TPP Revival Effort Leaves US Out In The Cold
• Pa. Appeals Court Upholds Risperdal Time Bar
• Fed. Circ. Clears Apotex In Neulasta Biosimilar Patent Row
• Pharma Salesman Cops To Defrauding NJ Insurance Programs
• No Damages For Promega In Gene-Testing IP Row: Fed. Circ.
• 10th Circ. Won't Revisit MusclePharm's SEC Probe Coverage
• 3 Fast Facts About Trump's Pick For HHS Chief
• Pelvic Mesh Jury Sides With J&J Unit In Houston
• Pharma Case Highlights Importance Of Unrebutted Evidence
• Key Considerations Before Leasing To Cannabis Businesses
• How Tax Reform Could Impact The Health Care Industry
• OvaScience Can't Duck IVF Treatment Suit, Shareholders Say
• Being There: Defending Depositions
• Trump Taps Vet Of BigLaw, Big Pharma As Next HHS Chief
• Endo Cert Bid Calls AGs' Use Of Private Attys Unconstitutional
• Grading Gottlieb: How Attys View FDA Chief's First 6 Months
• Retrophin CEO Says He Was Suspicious Of Ex-Katten Atty
• Allergan Can't Nix Antitrust Row As Buyer Class Is Certified
• Fed. Circ. Upholds Sanofi Win Over Generics In Multaq Suit
• Ex-Aveo Exec's Penalty In SEC Deal Up To Magistrate Judge
• Fla. Compounding Pharmacy Ducks Whistleblower's FCA Suit
• 9 Firms To Steer IPOs Exceeding $1.7B Amid Preholiday Rush
• A Tale Of 2 Cases On 3rd-Party Releases
• NY Agency Ordered To OK Speech Device For Disabled Girl
• BakerHostetler Hires Ex-Stroock Patent Partner In NY
• Janssen, Gilead Clear Mylan To Sell Generic HIV Drug
• Pa. County Launches Opioid Marketing RICO Suit
• The Legal Fallout For Harvey Weinstein's Hired Hands
• Actavis Ruling Bolsters Insurers In Opioid Coverage Battles
• Feds Fight Ex-Katten Atty's Effort To Savage Accountant
• Amneal Gets OxyContin Patent Nixed At PTAB
• Drinker Biddle Comms Keep Privilege In J&J Tampering Probe
• Affiliate Drug Discount Exempt From Antitrust Law, FTC Says
• Contentious Acquisition Changes Stay In Final Defense Bill
• Metropolitan Bank Leads 4 IPOs Totaling $372M
• DOJ Wins Bid To Halt Insider Trading Suit Against Doc
• Colo. Pot Company Fights IRS Power At Supreme Court
• Pa. Judge OKs Deposition In Xarelto Witness Tampering Row
• Jury Persuasion In An 'Alt-Fact' World
• 'End The Shenanigans,' FDA Chief Tells Big Pharma
• Arena Pharma, Investors Strike $24M Deal In Diet Drug Suit
• Russia Floats Conditions To Approve Bayer-Monsanto Deal
• Big Pharma Faces Insurance Hurdles In Opioid Suits
• Vet, Pharmacy Convicted Of Selling Opioid For Racehorses
• Investors Spar Over Damages In Valeant, Pershing Rows
• Radiation, Not J&J Talc, Caused Woman's Cancer, Jury Told
• Investor Says No Sham Deal Talks With Ex-Shkreli Atty
• Florida Time Share Co., Others Launch IPOs Totaling $336M
• Pharma Co. Behind Fentanyl Spray Seeks Out Of Investor Suit
• Heart Attack Not Worth Testim's Benefits, Patient Testifies
• Xarelto Trial Attys Spar Over Witness Tampering Accusations
• Allergan Making A 'Mockery' Of IPR Process, Lawmaker Says
• FDA Warning Wire: Salmonella At Food Plant
• Medtronic, Others Beat Catheter IP Suits With TC Heartland
• Actavis Not Owed Opioid Defense, Calif. Appeals Court Says
• Pillsbury Lands Ex-Latham Deal Pro In NY
• Al Jazeera Says MLBers Must Subpoena Journo In Libel Suit
• Deals Rumor Mill: Providence, Blackstone, Louis Dreyfus
• J&J Job Candidate Must Arbitrate Claims Against Recruiter
• Applying The Investors' Playbook To Legal Career Planning
• 'Asbestos' In J&J Talc Was False Positive, Jury Told
• Shkreli Investors Recount Few Dealings With Ex-Katten Atty
• Allergan Hit With Securities Suit Over Generics Price-Fixing
• Auxilium Ignored FDA's Limits On Testim's Use, Jury Told
• VC-Backed Stitch Fix Joins 6 IPO Launches Totaling $855M
• Janssen, Bayer Rigged Xarelto Trial, Philly Jury Hears
• Bayer Urges High Court To Deny Dow Appeal Of $455M Award
• Feds Fight Kimberly-Clark's Bid To Have FCA Suit Tossed
• Kentucky AG Sues Endo For Alleged Role In Opioid Crisis
• Medical Device Co. Accused Of Infringing RFID Patent
• The Law Firms Spinning The White House Turnstile
• Genocea Hit With Securities Suit After Herpes-Drug Flop
• What Trump's War On Regulations Means For Lawyers
• Has Trump Been Good For BigLaw?
• Who's Repping Whom? Law360's Guide To The Mueller Probe
• Valeant Sells Female Libido Drug Biz Amid Shareholder Suit
• IBio Sues German Research Co. In Widened IP Dispute
• J&J Talc Litigation Roundup
• Families Want Zofran MDL Paused To Beef Up Suit
• Demystifying Inherent Obviousness
• How IT And Procurement Pros Can Inform Law Firm Budgeting
• Pharma Cos. Can't Dodge Lidoderm Buyers' Antitrust MDL
• Ex-ArthroCare CEO Gets 20 Years For $750M Fraud
• Fed. Circ. Backs PTAB On Nixed Claims In Univ. Of Md. Patent
• DePuy Can't Block Ex-Employee's Work For Competitor
• Feds Say Pharma Trading Suspects Can't Get Early Win
• AbbVie Says Evidence Doesn't Back $140M AndroGel Verdict
• Janssen, Marketing Co. Can't Escape TCPA Suit After Spokeo
• 10 Firms To Steer IPOs Raising Near $2B As China Leads Way
• Xarelto User Faces Hard Sell In 1st Philly Mass Tort Trial
• Zoll Says Philips Can't Add $4M Interest To Patent Win
• FDA To Target Addictive Properties Of Opioids, Cigarettes
• Deals Rumor Mill: Broadcom, CVS, Belfius
• Feds Accuse Biotech Co., Execs Of 'Wide-Ranging Fraud'
• Auxilium Bellwether Latest Test For Testosterone Therapy Ads
• Alcon Must Show Exec Emails With Doc In Contact Lens MDL
• Health Hires: Jackson Lewis, EBG, Spencer Fane, AMRI
• NY Doc, Nurse Arrested For $2M Opioid Prescription Scheme
• Taxation With Representation: Skadden, Davis, Kirkland
• Bracing For A Life Sciences Enforcement Zeitgeist: Part 2
• Getting Real About Artificial Intelligence At Law Firms
• No Trace Of Mesothelioma In J&J Talc Miners, Jury Told
• Witness Left Firm Of Ex-Katten Atty's Relative, Jury Hears
• Covidien Fights Ex-Worker's Bid To Pause Contract Suit
• Drug Cos. Urge 3rd Circ. To Rethink Eye Drop Suit Ruling
• PE-Backed Evoqua Water Leads 4 IPOs Totaling $777M
• Deals Rumor Mill: T-Mobile, Novartis, TMF Group
• Philly Xarelto Warning Claims Not Preempted, Judge Rules
• FTC Notes Decline In Pay-For-Delay Drug Patent Settlements
• AIA Reviews Help Lower Drug Prices, High Court Hears
• Ex-Pharma Exec Admits Insider Trading On Cancer Drug Info
• Liberty Win Widens Split On SEC Probe Costs, 10th Circ. Told
• J&J Wins OK For $7M Aveeno Natural Labeling Settlement
• PE Shop Aisling Closes $280M Medical Therapies Fund
• AmerisourceBergen Eyes $575M FCA Deal After Criminal Plea
• Bracing For A Life Sciences Enforcement Zeitgeist: Part 1
• Proportionality, Not Perfection, Is What Matters
• Janssen Must Fork Over More Employee Info In Opioid Suit
• Investor Denies Contact With Ex-Katten Atty Before Deal
• Fed. Circ. Axes Bayer ED Drug Patent, Reversing Lower Court
• DAs Say 6,000 Cases Tied To Disgraced Drug Lab Chemist
• Hospitals Vow To Sue CMS Over Slashed 340B Reimbursement
• Gilead, Investors Dissect Word In $50M Drug Bonus Fight
• Ky. Sues Law Firm To Recover $4.2M From Oxycontin Deal
• Teva Beats Patent Claims Over Uceris Generic
• J&J Talc Plaintiff Wants 2nd Shot At Reviving $72M Award
• $20M Mexican Nutraceutical Row To Go To Arbitration
• Chuck Norris, Wife Say MRI Drug Threatened Her Life
• FDA Warns 4 Cos. On Pot Compound Cancer Claims
• Fed. Circ. Upholds Ruling That FluMist Didn't Kill Child
• White House Panel Urges Sweeping Action On Opioid Crisis
• Investors Say Perrigo Overpromised To Dodge Mylan Takeover
• Alaska, Ohio City Latest To Sue Over Opioid Marketing
• Deals Rumor Mill: Novartis, I-Med Radiology, Kaltura
• Fed. Circ. Clarifies Law For Functional Antibody Claims
• Make Way For The 'Unicorns'